WEBULL
WebtradeDownload

CME Group (CME) Stock Could Be 18% Overvalued Despite Record Trading Volume

Simply Wall St · 17h ago

CME Group has ridden a powerful wave of demand for its markets, and the stock is up strongly over the past few years, which raises a clear question for you as an investor: Is the current price really supported by the returns the business earns on the capital it puts to work?

  • Over the past 5 years the share price has gained 69.7%, so anyone looking at CME Group today needs to ask whether those gains line up with the durability and quality of the returns the company generates on its capital base.
  • Recent records in trading activity and revenue, including higher average daily volumes across multiple asset classes and greater use of crypto derivatives, can support expectations that CME Group has the opportunity to keep deploying capital into products that may sustain or improve its return profile.
  • If you'd rather focus on earnings, this one's for you. See what CME Group's 24.7x P/E says about the price.

The issue now is whether the returns CME Group earns on its capital are strong and resilient enough to justify where the stock trades today.

If you want a broader starting point for research alongside CME Group, a focused screen of 35 high quality undervalued stocks can help you compare how other businesses turn capital into returns.

Is CME Group Getting Expensive on Excess Returns?

The Excess Returns model looks at how much profit CME Group can earn over and above the return investors typically demand on its equity. In this framework, the analysis uses a Book Value of $74.31 per share and a Stable EPS of $13.92 per share, based on analyst estimates for future return on equity. With an Average Return on Equity of 16.70% and a Cost of Equity of $6.60 per share, the model calculates an Excess Return of $7.32 per share. This indicates CME Group is generating value on top of its capital base rather than just covering its funding cost.

Those economics are paired with a Stable Book Value of $83.35 per share, again grounded in forward-looking estimates, which together suggest a mature but still productive equity base. The Excess Returns output currently puts CME Group's estimated intrinsic value meaningfully below the share price of $304.06, so the market is assigning a rich multiple to those returns. Because CME Group reported record Q3 revenue and very high crypto and interest rate volumes in 2026, that premium gap likely reflects investors placing a high value on the durability of these excess profits rather than any short term trading spike. Find out what CME Group could be worth using our Excess Returns estimate.

The CME Group Narrative: What Would Justify Today's Price?

Narratives pick up where the valuation puzzle for CME Group leaves off and explain which paths for earnings, profitability and business scale would need to occur for the stock to be worth meaningfully more or less than it is today on Simply Wall St's Community page. Each scenario links its figures to a clear view on how CME Group's growth, margins and key risks might evolve, giving you a reference point you can revisit as fresh information becomes available.

One of the top community narratives on CME Group: roughly fairly valued

"The numbers and current valuation indicate that CME Group is fairly valued, with investors already accounting for strong margins and structural market data revenue..."

Discover why this Narrative puts CME Group at roughly fairly valued.

The CME Group share price is only one piece of the investment puzzle

CME Group's valuation story is important, but it is not the whole picture, because our broader checks have picked up specific concerns that investors may want to weigh before making any decision. Take a closer look at 2 warning signs before settling on a valuation.